SCHEMBL2997805

SCHEMBL2997805

COc1ccc(Cl)cc1S(=O)(=O)C1CCN(c2nc(-c3ccc(C)cc3)cs2)CC1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 11/20 0.52
RAB9A P51151 10/20 0.52
NPC1 O15118 8/20 0.52
MAPT P10636 8/20 0.46
NPSR1 Q6W5P4 2/20 0.46
CYP1A2 P05177 2/20 0.46
CYP2C9 P11712 2/20 0.46
CYP2C19 P33261 2/20 0.46
KMT2A Q03164 2/20 0.46
ALDH1A1 P00352 2/20 0.46
POLB P06746 1/20 0.46
HPGD P15428 1/20 0.46
HTT P42858 1/20 0.46
LMNA P02545 2/20 0.46
TSHR P16473 1/20 0.46
MAPK1 P28482 3/20 0.43
EGFR P00533 1/20 0.43
L3MBTL1 Q9Y468 2/20 0.41
KDM4E B2RXH2 1/20 0.41
NTSR1 P30989 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3006072 0.95 SMN1; SMN2 (0.50) SMN1; SMN2RAB9ANPC1MAPTNPSR1
SCHEMBL3009002 0.93 SMN1; SMN2 (0.45) SMN1; SMN2RAB9ANPC1MAPTNPSR1
SCHEMBL3005919 0.93 SMN1; SMN2 (0.57) SMN1; SMN2RAB9ANPC1MAPTNPSR1
SCHEMBL3016507 0.92 RAB9A (0.50) SMN1; SMN2RAB9ANPC1MAPTNPSR1
SCHEMBL3002520 0.92 SMN1; SMN2 (0.57) SMN1; SMN2RAB9ANPC1MAPTNPSR1
SCHEMBL3008094 0.92 SMN1; SMN2 (0.49) SMN1; SMN2RAB9ANPC1MAPTNPSR1
SCHEMBL3016836 0.91 SMN1; SMN2 (0.47) SMN1; SMN2RAB9ANPC1MAPTNPSR1
SCHEMBL3009561 0.90 SMN1; SMN2 (0.52) SMN1; SMN2RAB9ANPC1MAPTNPSR1
SCHEMBL3013673 0.90 RAB9A (0.46) SMN1; SMN2RAB9ANPC1MAPTNPSR1
SCHEMBL3008336 0.90 AR (0.50) SMN1; SMN2RAB9ANPC1MAPTNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA SMN1; SMN2 1/4885RAB9A 2943/4885NPC1 15/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.